Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpJournal of Hepatology
• journal#1
LETTER
Nahum Méndez-Sánchez, Alejandro Valencia-Rodríguez
No abstract text is available yet for this article.
March 27, 2020: Journal of Hepatology
#2
LETTER
George V Papatheodoridis, Pietro Lampertico
No abstract text is available yet for this article.
March 27, 2020: Journal of Hepatology
#3
LETTER
Zi-Yuan Zou, Jian-Gao Fan
No abstract text is available yet for this article.
March 27, 2020: Journal of Hepatology
#4
LETTER
Maren H Harms, Henk R van Buuren, Adriaan J van der Meer
No abstract text is available yet for this article.
March 26, 2020: Journal of Hepatology
#5
LETTER
Hyo Jung Park, Hye Young Jang, So Yeon Kim
No abstract text is available yet for this article.
March 26, 2020: Journal of Hepatology
#6
Xiaoqin Wu, Kyle L Poulsen, Carlos Sanz-Garcia, Emily Huang, Megan R McMullen, Sanjoy Roychowdhury, Srinivasan Dasarathy, Laura E Nagy
BACKGROUND & AIMS: Autophagy maintains cellular homeostasis and plays a critical role in the development of non-alcohol-related liver disease (NAFL/NASH). Insufficient autophagy can lead to hepatocellular injury and death. The pseudokinase mixed lineage kinase domain-like (MLKL) is a key downstream effector of receptor interacting protein kinase 3 (RIP3) in the necroptotic pathway of programmed cell death. However, recent data reveal that MLKL also regulates autophagy. Here we tested the hypothesis that MLKL contributes to the progression of Western diet-induced liver injury in mice by regulating autophagy...
March 24, 2020: Journal of Hepatology
#7
LETTER
Shahid A Khan, Oliver Clements, Jin Un Kim, Joseph Eliahoo
No abstract text is available yet for this article.
March 23, 2020: Journal of Hepatology
#8
Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals.
Mohsin Hassan, Sheida Moghadamrad, Marcel Sorribas, Sergi G Muntet, Philipp Kellmann, Coralie Trentesaux, Marie Fraudeau, Paolo Nanni, Witold Wolski, Irene Keller, Siegfried Hapfelmeier, Noah F Shroyer, Reiner Wiest, Beatrice Romagnolo, Andrea De Gottardi
BACKGROUND AND AIMS: Paneth cells (PCs) synthesize and secrete antimicrobial peptides that are key mediators of host-microbe interactions establishing a balance between intestinal microflora and enteric pathogens. We observed that their number increases in experimental portal hypertension and aimed to investigate the mechanisms by which these cells can contribute to the regulation of portal pressure. METHODS: We first treated Math1Lox/Lox VillcreERT2 mice with tamoxifen to induce the complete depletion of intestinal PCs...
March 20, 2020: Journal of Hepatology
#9
Alessandro Cucchetti, Matteo Serenari, Carlo Sposito, Stefano Di Sandro, Cristina Mosconi, Ilaria Vicentin, Enrico Garanzini, Vincenzo Mazzaferro, Luciano De Carlis, Rita Golfieri, Carlo Spreafico, Angelo Vanzulli, Vincenzo Buscemi, Matteo Ravaioli, Giorgio Ercolani, Antonio Daniele Pinna, Matteo Cescon
BACKGROUND: S AIMS: The weight of response to neo-adjuvant therapies, to select candidates with hepatocellular carcinoma (HCC) for liver transplantation (LT) at acceptable risk of recurrence, remains partially unsolved for most of post-LT prediction models. Aim of this study was to embed radiological response in the Metroticket 2.0 model for post-LT prediction of "HCC-related death" to provide more usefulness in the modern clinical scenario. METHODS: Data from 859 transplanted patients (2000-2015) who received neo-adjuvant therapies were included...
March 19, 2020: Journal of Hepatology
#10
LETTER
Christophe Corpechot, Alexandra Rousseau, Olivier Chazouillères
No abstract text is available yet for this article.
March 18, 2020: Journal of Hepatology
#11
EDITORIAL
Claire Francoz
No abstract text is available yet for this article.
March 17, 2020: Journal of Hepatology
#12
LETTER
Alexander Khoruts, Jasmohan S Bajaj
No abstract text is available yet for this article.
March 17, 2020: Journal of Hepatology
#13
LETTER
Cyriac Abby Philips, Rizwan Ahamed, Sasidharan Rajesh, Philip Augustine
No abstract text is available yet for this article.
March 17, 2020: Journal of Hepatology
#14
LETTER
Mingyang Jiang, Huachu Deng, Siyi Liu, Shanggui Su
No abstract text is available yet for this article.
March 17, 2020: Journal of Hepatology
#15
LETTER
Manisha Verma
No abstract text is available yet for this article.
March 17, 2020: Journal of Hepatology
#16
Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki, Takashi Watanabe, Masanobu Nakata, Rika Sakai, Noriyasu Fukushima, Takuya Fukushima, Yukiyoshi Moriuchi, Kuniaki Itoh, Kisato Nosaka, Ilseung Choi, Masashi Sawa, Rumiko Okamoto, Hideki Tsujimura, Toshiki Uchida, Sachiko Suzuki, Masataka Okamoto, Tsutomu Takahashi, Isamu Sugiura, Yasushi Onishi, Mika Kohri, Shinichiro Yoshida, Minoru Kojima, Hiroyuki Takahashi, Akihiro Tomita, Yoshiko Atsuta, Dai Maruyama, Eiji Tanaka, Takayo Suzuki, Tomohiro Kinoshita, Michinori Ogura, Ryuzo Ueda, Masashi Mizokami
BACKGROUND & AIMS: The purpose of this post hoc analysis was to evaluate the efficacy of an ultra-high sensitive HBsAg assay using prospectively stored samples of HBV DNA monitoring study for lymphoma patients with resolved HBV infection following anti-CD20 antibody, rituximab-containing chemotherapy (UMIN000001299). METHODS: HBV reactivation defined as HBV DNA levels of 11 IU/mL or more was confirmed in 22 of 252 patients. Conventional HBsAg assay (ARCHITECT, cut-off value: 0...
March 16, 2020: Journal of Hepatology
#17
Richard Moreau, Joan Clària, Ferran Aguilar, François Fenaille, Juan José Lozano, Christophe Junot, Benoit Colsch, Paolo Caraceni, Jonel Trebicka, Marco Pavesi, Carlo Alessandria, Frederik Nevens, Faouzi Saliba, Tania M Welzel, Agustin Albillos, Thierry Gustot, Javier Fernández, Christophe Moreno, Maurizio Baldassarre, Giacomo Zaccherini, Salvatore Piano, Sara Montagnese, Victor Vargas, Joan Genescà, Elsa Solà, William Bernal, Noémie Butin, Thaïs Hautbergue, Sophie Cholet, Florence Castelli, Christian Jansen, Christian Steib, Daniela Campion, Raj Mookerjee, Miguel Rodríguez-Gandía, German Soriano, François Durand, Daniel Benten, Rafael Bañares, Rudolf E Stauber, Henning Gronbaek, Minneke J Coenraad, Pere Ginès, Alexander Gerbes, Rajiv Jalan, Mauro Bernardi, Vicente Arroyo, Paolo Angeli
No abstract text is available yet for this article.
March 16, 2020: Journal of Hepatology
#18
Robert Montal, Daniela Sia, Carla Montironi, Wei Q Leow, Roger Esteban-Fabró, Roser Pinyol, Miguel Torres-Martin, Laia Bassaganyas, Agrin Moeini, Judit Peix, Laia Cabellos, Maeda Miho, Carlos Villacorta-Martin, Parissa Tabrizian, Leonardo Rodriguez-Carunchio, Giancarlo Castellano, Christine Sempoux, Beatriz Minguez, Timothy M Pawlik, Ismail Labgaa, Lewis R Roberts, Manel Sole, Maria I Fiel, Swan Thung, Josep Fuster, Sasan Roayaie, Augusto Villanueva, Myron Schwartz, Josep M Llovet
BACKGROUND AND AIMS: Cholangiocarcinoma (CCA), a deadly malignancy of the bile ducts, can be classified on the basis of its anatomical location into either intrahepatic (iCCA) or extrahepatic (eCCA), each with different pathogenesis and clinical management. There is marginal understanding of the molecular landscape of eCCA and no targeted therapy with clinical efficacy has been approved. We aimed to provide a molecular classification of eCCA and identify potential targets for molecular therapies...
March 12, 2020: Journal of Hepatology
#19
REVIEW
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Juan W Valle
Patients with biliary tract cancers (cholangiocarcinoma (CCA) and gallbladder cancer (GBC)) have a poor prognoses and incidence is increasing. Most patients are diagnosed with advanced disease when options of treatment are limited to palliative approaches, mainly focused on chemotherapy. In recent years, novel treatment targets of relevance to biliary tract cancers, mainly present in patients with intrahepatic cholangiocarcinoma (iCCA), have been identified and are rapidly changing the field. These include fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)-1 and -2 mutations which are each present in around 10-20% of patients with iCCA patients...
March 11, 2020: Journal of Hepatology
#20
Philip Starkey Lewis, Lara Campana, Niya Aleksieva, Jennifer Ann Cartwright, Alison Mackinnon, Eoghan O'Duibhir, Timothy Kendall, Matthieu Vermeren, Adrian Thomson, Victoria Gadd, Benjamin Dwyer, Rhona Aird, Tak-Yung Man, Adriano Giorgio Rossi, Lesley Forrester, Brian Kevin Park, Stuart John Forbes
BACKGROUND & AIM: Acute liver injury (ALI) can occur if a significant acetaminophen (APAP) overdose presents too late for n-acetylcysteine treatment, which risks deterioration into acute liver failure, systemic inflammation, and death. Macrophages influence the progression and resolution of ALI due to their innate immunological function and paracrine activity. Syngeneic primary bone-marrow derived macrophages (BMDMs) were tested as a cell-based therapy in a mouse model of APAP-ALI METHODS: Several phenotypically-distinct BMDM populations were delivered intravenously to APAP-ALI mice when hepatic necrosis was established, and then evaluated based on their effects on injury, inflammation, immunity, and regeneration...
March 10, 2020: Journal of Hepatology
Fetching more papers... 
